1. Introduction {#sec1}
===============

Msh homeobox 1 (MSX1) is a homeobox transcriptional factor involved in limb-pattern formation and craniofacial development and specifically in odontogenesis. Mouse*Msx1* mutations cause craniofacial malformation and tooth agenesis \[[@B1]\].*Msx1*-knockout mice show arrested tooth development at the bud stage and embryonic lethal defects \[[@B2]\]. Msx1 is expressed at high levels in craniofacial skeletal cells during early postnatal development \[[@B3]\], and transgenic mice expressing*Msx1* under the control of the alpha (I) collagen promoter exhibit increased osteoblast number, cell proliferation, and apoptosis \[[@B4]\], suggesting Msx1 may have a role in craniofacial bone modeling. MSX1 is also expressed at high levels in the dental mesenchyme at the cap and bell stages \[[@B5]\] and may be a suppressor for cell differentiation that maintains mesenchymal cells in a proliferative state to ensure robust craniofacial and tooth development \[[@B6]\]. In addition, MSX1 is an upstream and downstream regulator for the bone morphogenetic protein BMP2/BMP4 signaling pathway \[[@B7], [@B8]\]. Mutations in human*MSX1* also cause cleft lip/palate and tooth agenesis \[[@B9], [@B10]\]. However, the role of MSX1 in human craniofacial and tooth development has not been fully understood.

Dental pulp stromal cells isolated from whole pulp tissue can differentiate into osteoblasts, odontoblasts, endothelial cells, nerve cells, and adipocytes*in vitro*. Some of these cells identified by several cell surface antigens are referred to as dental pulp stem cells (DPSCs) \[[@B11], [@B12]\]. DPSCs may play a role in dentinogenesis/osteogenesis in both developing and injured teeth. Furthermore, these cells are a promising source of cell-based regenerative therapies for dental, skeletal, vascular, and neuronal diseases \[[@B13], [@B14]\]. Human DPSCs (hDPSCs) have not been fully characterized at the molecular level, but a previous reported showed that*MSX1* is expressed at higher levels in hDPSCs than in bone marrow-derived mesenchymal stem cells and fibroblasts \[[@B15]\]. MSX1 may participate in the control of primary or secondary dentin formation and reparative dentin or osteodentin/bone formation in injured pulp tissue, in addition to the physiological role such as the maintenance of dental pulp stem/progenitor cells in healthy teeth. In the present study, we explored the role of MSX1 in pulpal mesenchymal cells using human DPSCs in culture.

Statins are a class of drugs that function as specific inhibitors of 3-hydoroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, a rate-limiting enzyme in cholesterol synthesis. Numerous studies have shown that statins exert bone anabolic effects in osteoblasts and osteogenic precursor cells \[[@B16], [@B17]\]. Simvastatin enhances alveolar bone remodeling in the tooth extraction socket \[[@B18]\], enhances bone fracture healing \[[@B19]\], and reduces alveolar bone loss and tooth mobility in chronic periodontitis \[[@B20]\]. In addition, simvastatin enhances odontoblast/osteoblast differentiation of DPSCs and mesenchymal stem cells isolated from other tissues \[[@B17], [@B21], [@B22]\]. These studies indicate a close relationship between cholesterol synthesis and osteoblast differentiation.

Here, we demonstrated the role of MSX1 in osteoblast differentiation and cholesterol synthesis in hDPSCs using small interfering RNA (siRNA) against*MSX1*. DNA microarray analyses revealed that knockdown of*MSX1* in hDPSCs undergoing osteogenic differentiation abolished the expression of various osteoblast-related genes but enhanced the expression of cholesterol synthesis-related genes. Our results suggest that MSX1 enhances osteoblast differentiation and calcification in hDPSCs through repression of cholesterol synthesis genes and induction of osteoblast-related genes.

2. Material and Methods {#sec2}
=======================

2.1. Human DPSCs {#sec2.1}
----------------

Extracted healthy deciduous teeth were collected from 6--12-year-old children following protocols approved by the ethical authorities at Hiroshima University (permit number: D88-2). Written informed consent was obtained from the subject or subject\'s parent. Pulp tissue specimens from deciduous teeth were minced and digested with 3 mg/mL collagenase type I (Life Technologies, Carlsbad, CA, USA) and 4 mg/mL dispase (Roche Diagnostics, Mannheim, Germany) in Dulbecco\'s modified Eagle\'s medium (DMEM; Sigma, St. Louis, MO, USA) for 1 h at 37°C. Single cell suspension was obtained by passing cells through a 70 *μ*m cell strainer (CORNING, Corning, NY, USA). The cells were incubated in DMEM supplemented with 20% fetal bovine serum (FBS; Biowest, Nuaillé, France) and 1% penicillin-streptomycin (Life Technologies) at 37°C in 95% air and 5% CO~2~ \[[@B23]\]. Forming colonies were separated by incubation with Accutase (Funakoshi Co., Ltd., Tokyo, Japan), and isolated cells were transferred to passage cultures with DMEM supplemented by 10% FBS and 1% penicillin-streptomycin. The culture medium was changed every 2 days. Cells at passages 3--9 were used in subsequent experiments.

2.2. FACS Analysis {#sec2.2}
------------------

Cells were harvested with Accutase and fixed in 4% paraformaldehyde. Cells were centrifuged at 1,500 ×g for 5 min and resuspended at 5 × 10^6^ cells/mL in PBS containing 0.5% bovine serum albumin (BSA). Aliquots containing 10^5^ cells were incubated with individual phycoerythrin- (PE-) conjugated antibodies or isotype control PE-conjugated IgG*κ* for 30 min at room temperature and then washed in PBS supplemented with 3% FBS. Samples were analyzed using a FACS Aria flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and the data were analyzed using CELLQUEST software (Becton Dickinson). The following monoclonal antibodies were used: PE-conjugated antibodies against CD73 (mouse IgG1*κ*; Biolegend, San Diego, CA, USA), CD90 (mouse IgG1*κ*; Biolegend), CD105 (mouse IgG1*κ*; Biolegend), and CD166 (mouse IgG1*κ*; Santa Cruz Biotechnology, Texas, USA). PE-conjugated isotype control mouse IgG1*κ* (Biolegend) was used as the control.

2.3. *MSX1* Knockdown {#sec2.3}
---------------------

MSX1 siRNA oligonucleotides (s8999 and s224066) were purchased from Life Technologies. The sequences are 5′-GCAUUUAGAUCUACACUCUtt-3′ (sense) and 5′-AGAGUGUAGAUCUAAAUGCta-3′ (antisense) for s8999 and 5′-GCAAGA AAAGCGCAGAGAAtt-3′ (sense) and 5′-UUCUCUGCGCUUUUCUUGCct-3′ (antisense) for s224066. Silencer select negative control \#1 siRNA (Life Technologies) was used as the control.

Human DPSCs were seeded at 5 × 10^4^ cells/well in 24-multiwell plates coated with type I collagen with 0.5 mL DMEM supplemented with 10% FBS. After 24 h, siRNA was transfected into cells with Lipofectamine 2000 (Life Technologies) and cells were incubated for an additional 48 h.

2.4. Osteogenic Differentiation of hDPSCs and Alizarin Red Staining {#sec2.4}
-------------------------------------------------------------------

After the cultures became confluent, hDPSCs were incubated with 0.5 mL of DMEM supplemented with 10% FBS, 10 mM *β*-glycerophosphate (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), 50 *μ*g/mL ascorbic acid 2-phosphate (Sigma), 2 mM L-glutamine (Sigma), 100 nM dexamethasone (Sigma), and 1% penicillin/streptomycin (osteogenesis-induction medium) as described \[[@B15]\]. For evaluation of calcification, cells incubated with osteogenesis-induction medium for 14 days were fixed at room temperature in 95% ethanol for 10 min and stained with 1% alizarin red S for 30 min. The cell-matrix layers were washed 6 times with sterile water.

2.5. Alkaline Phosphatase Activity {#sec2.5}
----------------------------------

Human DPSCs were washed twice with saline and homogenized ultrasonically with 1% NP-40 in saline. Alkaline phosphatase activity was determined using Lab Assay ALP (Wako, Osaka, Japan). DNA concentration was determined with the Quant-iT*™* PicoGreen dsDNA Assay Kit (Life Technologies) to calculate alkaline phosphatase activity/*μ*g DNA.

2.6. Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR) {#sec2.6}
---------------------------------------------------------------------------

Total RNA was isolated and cDNA was synthesized as described \[[@B15]\]. The cDNA samples were amplified using Universal PCR Master Mix (Life Technologies) with primers ([Table 1](#tab1){ref-type="table"}) and TaqMan probes were purchased from Roche Diagnostics (Basel, Switzerland). GAPDH primers/probe set was used for normalization. After amplification of DNA, expression levels were determined with the ABI prism 7900 HT sequence detection system (Life Technologies).

2.7. DNA Microarray {#sec2.7}
-------------------

After the induction of osteogenic differentiation for 4 days, total RNA was isolated from MSX1-knockdown and control hDPSCs using TRIzol (Life Technologies, Japan) and an RNeasy Mini Kit (Qiagen, Chatsworth, CA). DNA microarray analysis was performed using the SurePrint G3 Human GE 8 × 60 K v2 Microarray (Agilent Technologies, Santa Clara, CA, USA). Raw data were standardized by the global median normalization method using GeneSpring (Silicon Genetics, Redwood City, CA, USA). The raw data were deposited in the Gene Expression Omnibus database (GSE69992).

2.8. Statistical Analysis {#sec2.8}
-------------------------

Results are expressed as mean ± SD. Differences between two groups were analyzed by two-way ANOVA with Tukey\'s*post hoc* test for multiple comparisons. In all analyses, *P* \< 0.05 indicated statistically significant differences between values.

3. Results {#sec3}
==========

3.1. Mesenchymal Stem Cell Markers Expressed in Cultured hDPSCs {#sec3.1}
---------------------------------------------------------------

Human DPSCs from postnatal human primary teeth were used to explore the functional role of MSX1. These cells exhibited a fibroblastic shape ([Figure 1(a)](#fig1){ref-type="fig"}) and showed expression of mesenchymal stem cell surface markers CD73 (\>90%), CD90 (\>90%), CD105 (\>10%), and CD166 (\>30%) ([Figure 1(b)](#fig1){ref-type="fig"}) as expected from previous studies \[[@B24]\].

3.2. *MSX1* Knockdown Abolishes Osteogenic Differentiation of hDPSCs {#sec3.2}
--------------------------------------------------------------------

Human DPSCs were transfected with two different siRNAs for*MSX1* or control siRNA and then exposed to osteogenesis-induction medium. Both siRNA oligonucleotides targeting*MSX1* (s8999 and s224066) abolished*MSX1* mRNA expression at 48 h and subsequent matrix calcification on day 14 ([Figure 2](#fig2){ref-type="fig"}). We selected*MSX1* siRNA (s8999) for subsequent studies.

Next, we examined the effect of*MSX1* knockdown on alkaline phosphatase activity and the expression of osteoblast-related genes in hDPSCs after the onset of osteogenesis ([Figure 3](#fig3){ref-type="fig"}). In hDPSCs transfected with control siRNA, alkaline phosphatase activity and*RUNX2*,*BMP2*, osterix*(OSX)*, osteocalcin (*OCN*; also known as*BGLAP*), and alkaline phosphatase liver type*(ALPL)* mRNA levels increased on days 4--12 after the onset of differentiation.*MSX1* mRNA levels also increased on days 4--12. However,*MSX1* knockdown abolished the induction of alkaline phosphatase activity ([Figure 3(a)](#fig3){ref-type="fig"}) and the increases in*ALPL*,*RUNX2*,*BMP2*,*OCN*, and*MSX1* mRNA levels, although it further increased*OSX* mRNA levels ([Figure 3(b)](#fig3){ref-type="fig"}). It should be noted that the incubation with MSX1 siRNA abolished MSX1 expression at least until day 12 after the onset of osteogenic differentiation.

Next, we examined whether MSX1 knockdown might influence the expression of other master genes including a master regulator of chondrogenesis*SOX9* and a master regulator of adipogenesis*PPARγ* ([Figure 4](#fig4){ref-type="fig"}). In control hDPSCs, no significant changes in the expressions of*SOX9* and*PPARγ* were observed after the exposure to osteogenesis-induction medium. Under these conditions, MSX1 knockdown increased the expression of*PPARγ* on days 4--8, although it had little effect on the expression level of*SOX9*.

3.3. *MSX1* Knockdown Downregulated and Upregulated a Variety of Genes {#sec3.3}
----------------------------------------------------------------------

To characterize the effects of*MSX1* knockdown on osteogenic differentiation, we performed DNA microarray analyses on day 4 after exposure to osteogenesis-induction medium.*MSX1* knockdown decreased and increased mRNA levels of 2923 and 3480 genes, respectively, which were selected with cut-off values of \>1.5-fold change and *t*-test *P* \< 0.05. Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"} show lists of downregulated and upregulated genes in*MSX1*-knockdown hDPSCs, respectively.

To understand MSX1 actions in hDPSCs differentiating into osteoblasts, we performed a gene-set approach using the 2923 downregulated and 3480 upregulated genes. The WikiPathways analysis showed that the*MSX1* knockdown downregulated various genes involved in focal adhesion, endochondral ossification, integrin-mediated cell adhesion, matrix metalloproteinases, calcium regulation, and insulin signaling ([Table 4](#tab4){ref-type="table"}), whereas it upregulated genes involved in sterol regulatory element-binding protein (SREBP) signaling, cholesterol biosynthesis, adipogenesis, and fatty acid biosynthesis ([Table 5](#tab5){ref-type="table"}). These findings revealed that MSX1 regulates various cellular processes in hDPSCs differentiating into osteoblasts.

3.4. *MSX1* Knockdown Upregulates Cholesterol Synthesis-Related Genes {#sec3.4}
---------------------------------------------------------------------

In*MSX1*-knockdown hDPSCs, "SREBP signaling" and "cholesterol biosynthesis" were the top 1st and 3rd upregulated gene sets, respectively ([Table 5](#tab5){ref-type="table"}). The SREBP2 master transcriptional factor regulates the expression of all genes encoding enzymes in cholesterol synthesis pathway \[[@B25]\]. Because cholesterol synthesis is closely linked with osteoblast differentiation \[[@B17]\], we examined the effect of*MSX1* knockdown on the expression of these genes. DNA microarray analyses showed that all cholesterol synthesis-related genes, including*SREBP2*, were significantly upregulated by*MSX1* knockdown on day 4 ([Figure 5(a)](#fig5){ref-type="fig"}). Quantitative RT-PCR analyses confirmed that*MSX1* knockdown increased*SREBP2*, 3-hydroxy-3-methylglutaryl-CoA synthase 1*(HMGCS1)*, HMG-CoA reductase*(HMGCR)*, farnesyl diphosphate synthase*(FDPS)*, Cytochrome P450 Family 51 Subfamily A Polypeptide 1*(CYP51A1)*, and 7-dehydrocholesterol reductase*(DHCR7)* mRNA levels ([Figure 5(b)](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

Previous studies showed that mouse MSX1 was implicated in craniofacial bone development \[[@B1], [@B2], [@B4]\]. In mouse embryos, MSX1 suppresses precocious differentiation and calcification in dental mesenchymal cells and maintains these cells in a proliferative state to ensure subsequent craniofacial and tooth development \[[@B6], [@B26]\]. High levels of osteoblast number, cell proliferation, and apoptosis in MSX1 transgenic mice suggest that MSX1 modulates mouse craniofacial bone modeling \[[@B4]\]. However, the role of MSX1 in human cells remains poorly understood. In the present study, we demonstrated that MSX1 plays an essential role in osteogenic differentiation of hDPSCs.

In human DPSC cultures,*MSX1* knockdown resulted in suppressed expression of*RUNX2*,*ALPL*,*BMP2*, and*OCN*. These results demonstrate that MSX1 modulated the major signaling/transcriptional pathways regulating hard tissue differentiation to enhance osteogenic potential of hDPSCs. However,*MSX1* knockdown unexpectedly increased the mRNA level of*OSX*, another transcriptional factor involved in osteoblast maturation. This indicates MSX1 does not activate the entire osteogenesis program, perhaps because MSX1 cooperates with other transcription factors to fully control osteogenesis.*MSX1* knockdown enhanced*PPARγ* expression under the osteogenesis-induced condition, suggesting that MSX1 negatively regulates adipogenic differentiation. MSX1 may direct hDPSCs into the osteoblast lineage by preventing them from differentiating into the adipogenic lineage.*MSX1* knockdown also resulted in downregulation of various genes involved in focal adhesion, integrin-mediated cell adhesion, matrix metalloproteinases, calcium regulation, insulin signaling, and other processes. The extensive effect of*MSX1* knockdown on the entire gene expression profile emphasizes a crucial role of MSX1 in hDPSCs undergoing differentiation into osteoblasts.

Bidirectional transcription of the*Msx1* gene has been previously reported \[[@B27]--[@B29]\]. In embryonic and newborn mice, sense and antisense*Msx1* transcripts are differently expressed during development. In 705IC5 mouse odontoblasts, overexpression of*Msx1* antisense RNA decreased the expression of*Msx1* sense transcript, whereas overexpression of*Msx1* sense RNA increased*Msx1* antisense transcript. Thus, expression of mouse*Msx1* is controlled by the balance of the two transcripts. In our experiments, however,*MSX1* antisense transcript was not detected during osteogenic differentiation of hDPSCs irrespective of siRNA knockdown of*MSX1* (data not shown). The presence of*MSX1* antisense transcript in humans has so far been reported only in the embryo. Therefore,*Msx1* antisense RNA does not seem to be involved in the MSX1 expression in hDPSCs. Under these conditions, the expression of*Msx1* sense transcripts was markedly depressed in hDPSCs after treatment with MSX1 siRNA, indicating that the knockdown experiments worked appropriately regardless of the presence or absence of the*Msx1* antisense transcript.

MSX2, a paralog of MSX1, has been shown to enhance osteogenic differentiation of various mesenchymal cells, including C3H10T1/2 cells and aorta myofibroblasts \[[@B30]--[@B32]\]. MSX1 and MSX2 activate aortic adventitial osteoprogenitors via overlapping yet distinct mechanisms \[[@B33]\]. MSX2, unlike MSX1, enhances*OSX* expression without an increase in*RUNX2* expression in aortic myofibroblasts \[[@B30]\], suggesting distinct actions of MSX1 and MSX2 in osteoblast differentiation.

The molecular mechanism by which MSX1 activates the differentiation program remains unclear. MSX1 regulates transcriptional activity of target genes either by directly binding to the specific DNA MSX1-binding motif (C/GTAATTG) or through interactions with other transcriptional regulators. Interestingly, MSX1 binds to various transcriptional regulators, including Sp1, Sp3, Dlx3, Dlx5, PAX3, PAX9, BarH-like homeobox 1/BARX1, and PIAS1 \[[@B34]--[@B37]\]. Depending on the partner in the complex, MSX1 activates or represses transcription in the MSX1-interacting network of transcription factors \[[@B26], [@B38]\]. Moreover, MSX1 modifies chromatin structure near target genes by histone methylation \[[@B35], [@B39]\]. The interactions of MSX1 with various transcriptional regulators may account for the extensive changes in the expression levels of many genes (\~6400) by*MSX1* knockdown.

Statins, drugs for hyperlipidemia, enhance osteogenic differentiation of various mesenchymal cells, including osteoblast precursor cells, mesenchymal stem cells, and DPSCs, by inhibiting the synthesis of farnesyl pyrophosphate, decreasing cellular cholesterol, and activating the Ras-PI3K-Akt/MAPK signaling pathway, thereby increasing the expression of BMP2 and RUNX2 \[[@B17]\], although the underlying mechanisms are still controversial. Statins also suppress osteoclast function and enhance mandibular bone formation*in vivo* \[[@B40]\]. Interestingly, a previous study showed that simvastatin induces odontoblast differentiation of hDPSCs*in vitro* and*in vivo* \[[@B22]\]. However, no studies have shown the involvement of transcription factor(s) in the control of cholesterol synthesis during osteoblast differentiation. Here we found for the first time that MSX1 suppresses the entire cholesterol synthesis pathway in osteoblast differentiating hDPSCs by repressing*SREBP2* and other related genes. This suppression of cholesterol synthesis may facilitate osteoblast differentiation. It is also interesting to note that various mutations in the cholesterol synthesis pathway, including 7-dehydrocholesterol reductase*(DHCR7)*, cause craniofacial anomalies including cleft palate, suggesting the role of cholesterol synthesis in craniofacial development \[[@B41]\].

In conclusion, here we revealed for the first time that MSX1 is indispensable for osteoblast-like differentiation and calcification in hDPSCs derived from deciduous teeth. Furthermore, MSX1 was found to modulate a wide variety of genes, including cholesterol synthesis-related genes, during osteogenic differentiation of hDPSCs. We have not examined the effects of MSX1 siRNA in definitive teeth, although MSX1 may also function as a positive regulator of osteogenesis in definitive teeth as MSX1 mRNA levels are high in both definitive and deciduous teeth \[[@B15]\]. Our findings will provide new insights into the role of MSX1 in development and repair of teeth and may be useful in DPSC-based regenerative therapy.
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![(a) A microscope image of cultured hDPSCs isolated from human primary teeth with no induction. (b) Positive expression of several cell surface antigens for mesenchymal stem cells, including CD73, CD90, CD105, and CD166, in hDPSCs. Similar cell surface antigen expression pattern was obtained with hDPSCs isolated from different donors (data not shown).](SCI2016-8035759.001){#fig1}

![Effects of*MSX1* knockdown on calcification of hDPSCs. hDPSCs were transfected with either MSX1 siRNA (s8999 or s224066) or control siRNA and incubated for 2 days in growth medium before the cultures became confluent. Thereafter, the cultures were exposed to osteogenesis-induction medium. (a) The calcified matrix was stained with alizarin red on day 14. (b)*MSX1* mRNA level was quantified by RT-qPCR at 48 h after transfection. Values are averages ±SD for three cultures. ^*∗∗*^ *P* \< 0.01.](SCI2016-8035759.002){#fig2}

![Effects of*MSX1* knockdown on the expression of osteogenic markers in hDPSCs. (a) Alkaline phosphatase activity in cultures was determined on days 0--12 after exposure to osteogenesis-induction medium. (b) The mRNA levels of osteoblast-related genes, including*RUNX2*,*BMP2*,*OSX*,*OCN*, and*ALPL*, along with the*MSX1* mRNA level were quantified by RT-qPCR on the indicated days. Values are averages ±SD for three cultures. ^*∗*^ *P* \< 0.05; ^*∗∗*^ *P* \< 0.01.](SCI2016-8035759.003){#fig3}

![Effects of*MSX1* knockdown on the expression of the master genes of chondrogenesis and adipogenesis in hDPSCs. The mRNA levels of*SOX9* and*PPARγ* in hDPSCs transfected with MSX1 siRNA or control siRNA were quantified by RT-qPCR on the indicated days. Values are averages ±SD for 3 cultures. ^*∗∗*^ *P* \< 0.01; NS: not significant.](SCI2016-8035759.004){#fig4}

![Effects of*MSX1* knockdown on the expression of cholesterol synthesis-related genes, which are direct targets for SREBP2, in hDPSCs. (a) The cholesterol biosynthesis pathway is shown and the bold frames indicate target genes for the master transcriptional factor SREBP2. Microarray analysis indicates all genes involved in cholesterol synthesis are upregulated by*MSX1* knockdown. The numbers in brackets represent the fold changes in gene expression in*MSX1*-knockdown cells as compared with the control cells. (b) The mRNA levels of genes relevant to cholesterol synthesis, including*SREBP2*,*HMGCS1*,*HMGCR*,*FDPS*,*CYP51A1*, and*DHCR7*, were quantified by RT-qPCR analysis. Values are averages ±SD for three cultures. ^*∗∗*^ *P* \< 0.01; ^*∗∗∗*^ *P* \< 0.001.](SCI2016-8035759.005){#fig5}

###### 

Primer and probe sequences used for RT-qPCR.

  Gene                          Primer (5′ → 3′)              Probe
  ----------------------------- ----------------------------- -----------------------------------
  MSX1 (sense)                  F: CTCGTCAAAGCCGAGAGC         Roche Universal Probe \# 7
  R: CGGTTCGTCTTGTGTTTGC                                      
  MSX1 (antisense)              F: GCCAGCCCTCTTAGAAACAG       Roche Universal Probe \# 50
  R: AATAAAGCAGCCCCTCGTTC                                     
  RUNX2                         F: CAGTGACACCATGTCAGCAA       Roche Universal Probe \# 66
  R: GCTCACGTCGCTCATTTTG                                      
  BMP2                          F: CGGACTGCGGTCTCCTAA         Roche Universal Probe \# 49
  R: GGAAGCAGCAACGCTAGAAG                                     
  OSX                           F: CAGCAGCTAAACTTGGAAGGA      Roche Universal Probe \# 76
  R: TGCTTTCGCTTGTCTGAGTC                                     
  OCN                           F: GCCTCCTGAAAGCCGATGT        5′-CCAACTCGTCACAGTCCGGATTGAGCT-3′
  R: AAGAGACCCAGGCGCTACCT                                     
  ALPL                          F: TCACTCTCCGAGATGGTGGT       Roche Universal Probe \# 12
  R: GTGCCCGTGGTCAATTCT                                       
  SOX9                          F: GTACCCGCACTTGCACAAC        Roche Universal Probe \# 61
  R: TCTCGCTCTCGTTCAGAAGTC                                    
  PPAR*γ*                       F: GACAGGAAAGACAACAGACAAATC   Roche Universal Probe \# 7
  R: GGGGTGATGTGTTTGAACTTG                                    
  SREBP2                        F: GCCCTGGAAGTGACAGAGAG       Roche Universal Probe \# 21
  R: TGCTTTCCCAGGGAGTGA                                       
  HMGCS1                        F: TCTGTCTACTGCAAAAAGATCCAT   Roche Universal Probe \# 59
  R: TGAAGCCAAAATCATTCAAGG                                    
  HMGCR                         F: GTTCGGTGGCCTCTAGTGAG       Roche Universal Probe \# 65
  R: GCATTCGAAAAAGTCTTGACAAC                                  
  FDPS                          F: GGCCACTCCAGAACAGTACC       Roche Universal Probe \# 75
  R: CCTCATATAGCGCCTTCACC                                     
  CYP51A1                       F: TGCAGATTTGGATGGAGGTT       Roche Universal Probe \# 64
  R: CCTTGATTTCCCGATGAGC                                      
  DHCR7                         F: GCCATGGTCAAGGGCTAC         Roche Universal Probe \# 60
  R: TTGTAAAAGAAATTGCCTGTGAAT                                 

MSX1: msh homeobox 1; RUNX2: runt-related transcription factor-2; BMP2: bone morphogenetic protein-2; OSX: osterix; OCN: osteocalcin; ALPL: alkaline phosphatase liver type; SOX9: SRY- (sex determining region Y-) box 9; PPAR*γ*: peroxisome proliferator activated receptor gamma; SREBP2: sterol regulatory element-binding protein 2; HMGCS1: 3-hydroxy-3-methylglutaryl-CoA synthase 1; HMGCR: HMG-CoA reductase; FDPS: farnesyl diphosphate synthase; CYP51A1: Cytochrome P450 Family 51 Subfamily A Polypeptide 1; DHCR7: 7-dehydrocholesterol reductase; F: forward; R: reverse.

###### 

The list of downregulated genes in MSX1-knockdown cells (top 50).

  Gene symbol   Gene name                                                                             Gene ID        Fold change
  ------------- ------------------------------------------------------------------------------------- -------------- -------------
  C11orf96      Chromosome 11 open reading frame 96                                                   NM_001145033   92.53
  JAM2          Junctional adhesion molecule 2                                                        NM_021219      70.90
  MLC1          Megalencephalic leukoencephalopathy with subcortical cysts 1                          NM_015166      65.56
  NPPC          Natriuretic peptide C                                                                 NM_024409      54.40
  CPXM1         Carboxypeptidase X (M14 family), member 1                                             NM_019609      51.08
  EFCC1         EF-hand and coiled-coil domain containing 1                                           NM_024768      44.56
  SFRP4         Secreted frizzled-related protein 4                                                   NM_003014      43.96
  JAM2          Junctional adhesion molecule 2                                                        NM_021219      38.31
  LOC200772     Uncharacterized LOC200772                                                             NR_033841      34.41
  S100A8        S100 calcium binding protein A8                                                       NM_002964      31.72
  JAM2          Junctional adhesion molecule 2                                                        NM_001270408   31.42
  CPXM1         Carboxypeptidase X (M14 family), member 1                                             NM_019609      29.44
  SFRP4         Secreted frizzled-related protein 4                                                   NM_003014      28.11
  KIT           v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog                         NM_000222      27.48
  CLCA2         Chloride channel accessory 2                                                          NM_006536      24.88
  LINC00473     Long intergenic nonprotein coding RNA 473                                             NR_026860      24.34
  ST8SIA4       ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4                          NM_005668      24.16
  TEX29         Testis expressed 29                                                                   NM_152324      23.52
  PTGDR2        Prostaglandin D2 receptor 2                                                           NM_004778      23.31
  CXCL14        Chemokine (C-X-C motif) ligand 14                                                     NM_004887      22.63
  HS6ST2        Heparan sulfate 6-O-sulfotransferase 2                                                NM_001077188   22.61
  CHST15        Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) Sulfotransferase 15                NM_015892      21.84
  PIANP         PILR alpha associated neural protein                                                  NM_153685      21.67
  SNAP25        Synaptosomal-associated protein, 25 kDa                                               NM_003081      21.55
  CBLN2         Cerebellin 2 precursor                                                                NM_182511      21.30
  FRAS1         Fraser syndrome 1                                                                     NM_025074      21.24
  SECTM1        Secreted and transmembrane 1                                                          NM_003004      20.76
  NFE2          Nuclear factor, erythroid 2                                                           NM_006163      20.46
  GABBR2        Gamma-aminobutyric acid (GABA) B receptor, 2                                          NM_005458      19.22
  MSX1          Msh homeobox 1                                                                        NM_002448      19.08
  SCARA5        Scavenger receptor class A, member 5 (putative)                                       NM_173833      18.79
  PRSS35        Protease, serine, 35                                                                  NM_153362      18.60
  WNT2B         Wingless-type MMTV integration site family, member 2B                                 NM_004185      17.95
  BMP2          Bone morphogenetic protein-2                                                          NM_001200      17.63
  NDRG4         NDRG family member 4                                                                  NM_022910      17.39
  CRTAM         Cytotoxic and regulatory T cell molecule                                              NM_019604      16.80
  RASL12        RAS-like, family 12                                                                   NM_016563      15.91
  THBD          Thrombomodulin                                                                        NM_000361      15.26
  CHST1         Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1                               NM_003654      14.90
  DIO3OS        DIO3 opposite strand/antisense RNA (head to head)                                     NR_002770      14.81
  CCR1          Chemokine (C-C motif) receptor 1                                                      NM_001295      14.81
  TMEM35        Transmembrane protein 35                                                              NM_021637      14.79
  HAS1          Hyaluronan synthase 1                                                                 NM_001523      14.68
  SCN1B         Sodium channel, voltage-gated, type I, beta subunit                                   NM_199037      14.34
  ADAMTS17      ADAM metallopeptidase with thrombospondin type 1 motif, 17                            NM_139057      14.12
  GALNT15       UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15   NM_054110      13.86
  RHOH          Ras homolog family member H                                                           NM_004310      13.80
  GPR68         G protein-coupled receptor 68                                                         NM_003485      13.63
  TAC3          Tachykinin 3                                                                          NM_013251      13.37
  MIR1247       MicroRNA 1247                                                                         AF469204       13.13

###### 

The list of upregulated genes in MSX1-knockdown cells (top 50).

  Gene symbol    Gene name                                                           Gene ID        Fold change
  -------------- ------------------------------------------------------------------- -------------- -------------
  MLXIPL         MLX interacting protein-like                                        NM_032951      74.63
  CRLF1          Cytokine receptor-like factor 1                                     NM_004750      73.44
  ATP1A2         ATPase, Na+/K+ transporting, alpha 2 polypeptide                    NM_000702      69.84
  MAP2           Microtubule-associated protein 2                                    NM_002374      62.64
  PRODH          Proline dehydrogenase (oxidase) 1                                   NM_016335      50.32
  LONRF3         LON peptidase N-terminal domain and ring finger 3                   NM_001031855   30.84
  ERICH2         Glutamate-rich 2                                                    XM_001714892   29.67
  DMD            Dystrophin                                                          NM_004010      27.91
  SAA1           Serum amyloid A1                                                    NM_000331      26.65
  CLDN20         Claudin 20                                                          NM_001001346   24.19
  DMD            Dystrophin                                                          NM_004021      21.88
  PLIN4          Perilipin 4                                                         NM_001080400   21.64
  RLBP1          Retinaldehyde binding protein 1                                     NM_000326      21.22
  SAA2           Serum amyloid A2                                                    NM_030754      20.98
  PARD6B         Par-6 family cell polarity regulator beta                           NM_032521      19.56
  ANO3           Anoctamin 3                                                         NM_031418      17.58
  KCNJ16         Potassium inwardly rectifying channel, subfamily J, member 16       NM_170741      17.41
  LOC284561      Uncharacterized LOC284561                                           XR_110828      16.52
  USP53          Ubiquitin specific peptidase 53                                     NM_019050      16.47
  CLGN           Calmegin                                                            NM_004362      16.35
  USP53          Ubiquitin specific peptidase 53                                     NM_019050      16.15
  PLCE1-AS1      PLCE1 antisense RNA 1                                               NR_033969      15.15
  KLHDC7B        Kelch domain containing 7B                                          NM_138433      14.44
  PSG9           Pregnancy specific beta-1-glycoprotein 9                            NM_002784      14.23
  ERICH2         Glutamate-rich 2                                                    XM_001714892   13.66
  ANKRD1         Ankyrin repeat domain 1 (cardiac muscle)                            NM_014391      13.58
  PDE6A          Phosphodiesterase 6A, cGMP-specific, rod, alpha                     NM_000440      13.23
  COL4A4         Collagen, type IV, alpha 4                                          NM_000092      12.98
  PLAC8          Placenta-specific 8                                                 NM_016619      12.85
  BEST2          Bestrophin 2                                                        NM_017682      12.72
  IP6K3          Inositol hexakisphosphate kinase 3                                  NM_054111      12.22
  DNAH2          Dynein, axonemal, heavy chain 2                                     NM_020877      12.07
  INHBB          Inhibin, beta B                                                     NM_002193      11.63
  LOC100506544   Uncharacterized LOC100506544                                        AK057177       10.9
  TMEM125        Transmembrane protein 125                                           NM_144626      10.57
  ORM2           Orosomucoid 2                                                       NM_000608      10.51
  PCSK9          Proprotein convertase subtilisin/kexin type 9                       NM_174936      10.17
  CD200          CD200 molecule                                                      NM_001004196   9.99
  MFSD2A         Major facilitator superfamily domain containing 2A                  NM_001136493   9.85
  IL8            Interleukin 8                                                       NM_000584      9.80
  FMO6P          Flavin containing monooxygenase 6 pseudogene                        NR_002601      9.60
  C6             Complement component 6                                              NM_000065      9.54
  DSCR8          Down syndrome critical region gene 8                                NR_026838      9.23
  LOC648149      Uncharacterized LOC648149                                           AK123349       9.19
  GPR18          G protein-coupled receptor 18                                       NM_005292      9.14
  ORM1           Orosomucoid 1                                                       NM_000607      9.04
  GATA3          GATA binding protein 3                                              NM_001002295   9.03
  KCNB1          Potassium voltage-gated channel, Shab-related subfamily, member 1   NM_004975      8.97
  OCA2           Oculocutaneous albinism II                                          NM_000275      8.90
  PDZRN4         PDZ domain containing ring finger 4                                 NM_013377      8.86

###### 

The WikiPathways analysis selected gene sets significantly downregulated in MSX1-knockdown cells.

  Ranking   Pathway                                              *P* value      Gene counts (gene number of pathway)
  --------- ---------------------------------------------------- -------------- --------------------------------------
  1         Focal adhesion                                       4.20*E* − 09   36 (188)
  2         IL-4 signaling pathway                               2.55*E* − 05   13 (55)
  3         Endochondral ossification                            6.27*E* − 05   14 (64)
  4         Muscle cell tarbase                                  7.95*E* − 05   41 (336)
  5         Integrin-mediated cell adhesion                      8.22*E* − 05   18 (99)
  6         Matrix metalloproteinases                            9.72*E* − 05   9 (31)
  7         Regulation of toll-like receptor signaling pathway   1.12*E* − 04   22 (150)
  8         Calcium regulation in the cardiac cell               1.30*E* − 04   23 (149)
  9         MicroRNAs in cardiomyocyte hypertrophy               3.35*E* − 04   15 (105)
  10        Insulin signaling                                    4.14*E* − 04   23 (161)

###### 

The WikiPathways analysis selected gene sets significantly upregulated in MSX1 knockdown cells.

  Ranking   Pathway                                                *P* value        Gene counts (gene number of pathway)
  --------- ------------------------------------------------------ ---------------- --------------------------------------
  1         SREBP signalling                                       \<1.00*E* − 44   24 (50)
  2         Lymphocyte tarbase                                     \<1.00*E* − 44   78 (420)
  3         Cholesterol biosynthesis                               1.86*E* − 17     16 (17)
  4         Muscle cell tarbase                                    1.78*E* − 10     65 (336)
  5         Epithelium tarbase                                     9.47*E* − 10     52 (278)
  6         Folate metabolism                                      1.47*E* − 09     22 (68)
  7         Adipogenesis                                           3.19*E* − 08     30 (131)
  8         Leukocyte tarbase                                      1.47*E* − 07     28 (128)
  9         Fatty acid biosynthesis                                1.73*E* − 06     10 (22)
  10        SREBF and miR33 in cholesterol and lipid homeostasis   8.09*E* − 06     8 (18)

[^1]: Academic Editor: Gary E. Lyons
